Filtros de búsqueda

Lista de obras de Daniel Podzamczer

A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study ⬇️

artículo científico publicado el 1 de noviembre de 2003

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks

artículo científico publicado en 2009

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

artículo científico publicado en 2002

A review of nelfinavir for the treatment of HIV infection

artículo científico publicado en 2006

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

artículo científico publicado en 2009

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

artículo científico publicado en 2010

Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients

artículo científico publicado en 2010

Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013

artículo científico publicado en 2013

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

artículo científico publicado en 2014

Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression

artículo científico publicado en 2015

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy

artículo científico publicado en 2017

Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study

artículo científico publicado en 2014

Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study

artículo científico publicado en 2015

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

artículo científico publicado en 2017

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily

artículo científico publicado en 2014

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

artículo científico

Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily

artículo científico publicado en 2015

Clinical perspectives on human genetic screening to prevent nevirapine toxicity

artículo científico publicado en 2012

Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status

artículo científico publicado en 2015

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease

artículo científico publicado en 2015

Conclusions. Position of rilpivirine in the management of infection by the human immunodeficiency virus

artículo científico publicado en 2013

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

artículo científico publicado en 2003

Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components

artículo científico publicado en 2016

Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy

artículo científico publicado en 2011

Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

artículo científico publicado en 2015

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI.

artículo científico publicado en 2014

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial

artículo científico publicado en 2014

Discontinuation of Primary and SecondaryToxoplasma gondiiProphylaxis Is Safe in HIV‐Infected Patients after Immunological Restoration with Highly Active Antiretroviral Therapy: Results of an Open, Randomized, Multicenter Clinical Trial

article

Dual antiretroviral therapy: finding a place in the battle

artículo científico publicado en 2016

Early virological failure with a combination of tenofovir, didanosine and efavirenz.

artículo científico publicado en 2005

Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression

artículo científico publicado en 2009

Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort

artículo científico publicado en 2006

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients

artículo científico publicado en 2014

Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml

artículo científico publicado en 2014

Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group

artículo científico publicado en 2014

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

artículo científico publicado en 2009

Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression

artículo científico publicado en 2009

Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy

artículo científico publicado en 2005

Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).

artículo científico

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

artículo científico

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

artículo científico publicado en 2016

Extracutaneous atypical syphilis in HIV-infected patients

artículo científico publicado en 2017

Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine

artículo científico publicado en 2003

Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz

artículo científico publicado en 2007

HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain

artículo científico publicado en 2009

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.

artículo científico publicado en 2016

Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.

artículo científico publicado en 2004

How much fat loss is needed for lipoatrophy to become clinically evident?

artículo científico publicado en 2009

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

artículo científico publicado en 2015

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Ad

artículo científico publicado en 2010

Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

artículo científico publicado en 2004

Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

artículo científico

Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults

artículo científico publicado en 2011

Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study

artículo científico publicado en 2008

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

artículo científico publicado en 2012

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

artículo científico publicado en 2007

Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine

artículo científico

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study) ⬇️

artículo científico publicado el 24 de abril de 2011

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

artículo científico publicado en 2017

Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice

artículo científico publicado en 2014

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir

artículo científico publicado en 2011

Maraviroc Concentrations in Seminal Plasma in HIV-Infected Patients ⬇️

artículo científico publicado el 15 de diciembre de 2010

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

artículo científico publicado en 2010

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study

artículo científico publicado en 2013

Mechanisms of action, pharmacology and interactions of dolutegravir

artículo científico publicado en 2015

Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

artículo científico publicado en 2005

Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less

artículo científico publicado en 2004

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

artículo científico publicado en 2013

Peak bone mass in young HIV-infected patients compared with healthy controls

artículo científico publicado en 2014

Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index

artículo científico publicado en 2015

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes

artículo científico

Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir

artículo científico publicado en 2009

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

artículo científico publicado en 2010

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC.

artículo científico publicado en 2014

Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial

artículo científico publicado en 2014

Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.

artículo científico publicado en 2002

Restoration of T Cell Responses to Toxoplasma gondii after Successful Combined Antiretroviral Therapy in Patients with AIDS with Previous Toxoplasmic Encephalitis

article

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection

artículo científico publicado en 2016

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2014

Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients

artículo científico publicado en 2009

Short Communication: High Effectiveness of Etravirine in Routine Clinical Practice in Treatment-Experienced HIV Type 1-Infected Patients

article

Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

artículo científico publicado en 2014

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function

artículo científico publicado en 2012

Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients

artículo científico publicado en 2012

Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results

artículo científico publicado en 2007

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

artículo científico publicado en 2003

Switch strategies in antiretroviral therapy regimens

artículo científico publicado en 2014

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

artículo científico publicado en 2017

Switching strategies to improve lipid profile and morphologic changes

artículo científico publicado en 2006

Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study

article

Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients

artículo científico publicado en 2015

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

artículo científico publicado en 2015

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.

artículo científico publicado en 2017

The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals

article

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial

artículo científico publicado en 2015

The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy

artículo científico

Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

article

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent ⬇️

artículo científico publicado el 19 de junio de 2011

Toxoplasma myocarditis: a rare but serious complication in an HIV-infected late presenter

artículo científico publicado en 2016

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

artículo científico publicado en 2010

Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient

artículo científico publicado en 2010

Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study

artículo científico publicado en 2008

[Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients].

artículo científico publicado en 2002

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda